GE HealthCare Technologies’ GEHC MIM Software recently announced the receipt of FDA clearance for performing Centiloid ...

Positron emission tomography (PET) beta-amyloid imaging is a vital tool in the diagnosis and treatment of Alzheimer’s disease. Fortunately, the Centers for Medicare and Medicaid Services (CMS ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

The GE HealthCare imaging tool is coming out as pharma companies release new therapies onto the market to help treat the ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

With FDA 510(k) clearance, MIMneuro may perform positron emission tomography-based imaging analysis of amyloid plaque, GE ...

Increasingly, researchers are looking to develop blood tests that could help make Alzheimer's diagnosis faster, more accurate ...

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

After more than a century since Alois Alzheimer's description of an “unusual illness of the cerebral cortex”, the development ...

The clearance adds a Centiloid scale tool to GE Healthcare’s Mim software to help clinicians determine the density of amyloid ...